Psychedelics
atai Life Sciences Advances VLS-01 for Treatment-Resistant Depression
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Dr Srinivas Rao discusses the company’s development candidate VLS-01, aimed at treating…
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) chief scientific officer Dr Srinivas Rao discusses the company’s development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive’s Stephen Gunnion.
Rao explained that VLS-01 is a formulation of DMT, the active component in ayahuasca, known for its short-duration psychedelic effects. The innovation lies in its delivery method, an oral transmucosal film, resembling a Listerine strip, which dissolves inside the mouth over 20 minutes, providing a patient-friendly alternative to intravenous administration. Rao said this approach is designed to enhance the patient and healthcare provider experience, especially in settings not equipped for IV treatments.
The ongoing Phase 1B trial seeks to confirm VLS-01’s safety, tolerability, pharmacokinetics (PK), and pharmacodynamics, aiming for a psychoactive effect lasting 30-45 minutes with patients returning to baseline within two hours post-administration. Rao said this trial format follows the US treatment paradigm established by Spravato (esketamine) for depression. The trial will involve 16 healthy volunteers to assess the drug’s impact, setting a baseline with intravenous DMT before testing up to three oral doses of VLSI-01.
Initial results are expected in the second half of the year, with plans to proceed to Phase 2 trials involving patients with treatment-resistant depression to evaluate the compound’s efficacy further.
-
Psilocybin1 week ago
The Psychedelic Scene in Oaxaca, Mexico
-
Law & Regulation4 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics5 days ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics5 days ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics6 days ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
-
Ketamine1 week ago
Reunion Neuroscience raises $103 million
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com